Gilead Sciences agreed to acquire Tubulis, a German biotechnology company focused on antibody-drug conjugates (ADCs), for up to $4.8 billion, with an upfront cash consideration of $3.15 billion and contingent milestone payments up to $1.85 billion.
| Acquirer: | Gilead Sciences |
| Target: | Tubulis |
| Deal value (upfront + milestones): | $4.8bn |
| Type of deal: | Acquisition |
| Date closed: | 2026-04-07 |
| Buy-side advisors: | Centerview Partners, Allen & Company |
| Sell-side advisors: | Armory Securities |
| Legal buy-side: | Covington & Burling, Arnold & Porter Kaye Scholer |
| Legal sell-side: | Goodwin Procter |
Deal mechanics
Gilead Sciences has agreed to acquire Tubulis in a deal that includes an upfront payment of $3.15 billion, along with potential milestone payments totaling up to $1.85 billion.
Strategic rationale
The acquisition aims to bolster Gilead’s capabilities in developing and delivering next-generation antibody-drug conjugates (ADCs). Tubulis’s platform technology is designed to selectively deliver a variety of payloads to tumors, which could enhance patient outcomes. This strategic move underscores Gilead's commitment to advancing oncology treatments through innovative technologies.
Financial context
The deal value includes significant contingent milestone payments that are tied to the successful development and commercialization of Tubulis’s pipeline products. These milestones can provide an additional $1.85 billion in potential revenue, reflecting Gilead's confidence in the product’s future.
Advisors
Gilead Sciences was advised by Centerview Partners and Allen & Company on this deal. Tubulis worked with Armory Securities to secure the transaction.
Outlook
This acquisition positions Gilead as a leader in ADC technology, potentially setting the stage for further developments in oncology treatments. The strategic addition of Tubulis’s assets and platforms will be instrumental in expanding Gilead's therapeutic offerings.